Protein levels of glycogen synthase 3 kinase are normal in progressive supranuclear palsy

Neuroscience Letters

Volumn 366, Issue 1, 2004, Pages 67-70

  Borghi, Roberta ^a   Piccini, Alessandra ^a   Delacourte, Andrè ^b   Strocchi, Paola ^c   Zaccheo, Damiano ^a   Tabaton, Massimo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b INSERM   (France)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

GSK3; Progressive supranuclear palsy; Tau phosphorylation

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA;

ADULT; AGED; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; BRAIN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOBLOTTING; ISOENZYMES; MIDDLE AGED; PHOSPHORYLATION; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 3242696195     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.05.014     Document Type: Article

References (20)

1. Albers D.S., Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural Transm. Suppl. 59:2000;133-154
2. Baker M., Litvan I., Houlden H., Adamson J., Dickson D., Perez-Tur J., Hardy J., Lynch T., Bigio E., Hutton M. Association of an extended haplotype in tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8:1999;711-715
3. Baum L., Hansen L., Masliah E., Saitoh T. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. Mol. Chem. Neuropathol. 29(2-3):1996;253-261
4. Borghi R., Giliberto L., Assini A., Delacourte A., Perry G., Smith M.A., Strocchi P., Zaccheo D., Tabaton M. Increase of CDK5 is related to neurofibrillary pathology in progressive supranuclear palsy. Neurology. 58(4):2002;589-592
5. Dickson D.W. Neurodegenerative diseases with cytoskeletal pathology: a biochemical classification. Ann. Neurol. 42:1997;541-544
6. Di Maria E., Tabaton M., Vigo T., Abbruzzese G., Bellone E., Donati C., Frasson E., Marchese R., Montagna P., Munoz D.G., Pramstaller P.P., Zanusso G., Ajmar F., Mandich P. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann. Neurol. 47:2000;374-377
7. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 107(2):1980;519-527
8. Ferrer I., Barrachina M., Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. (Berl.). 104(6):2002;583-591
9. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359(Pt. 1):2001;1-16
10. Harr S.D., Hollister R.D., Hyman B.T. Glycogen synthase kinase 3 alpha and 3 beta do not colocalize with neurofibrillary tangles. Neurobiol. Aging. 17(3):1996;343-348
11. Leroy K., Boutajangout A., Authelet M., Woodgett J.R., Anderton B.H., Brion J.P. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol. (Berl.). 103(2):2002;91-99. (Epub: 2001, November 29)
12. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20(12):2001;27-39
13. Mattson M.P., Fu W., Waeg G., Uchida K. 4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. Neuroreport. 7:1997;2275-2281
14. Odetti P., Garibaldi S., Norese R., Angelini G., Marinelli L., Valentini S., Menini S., Traverso N., Zaccheo D., Siedlak S., Perry G., Smith M.A., Tabaton M. Lipoperoxidation is selectively involved in progressive supranuclear Palsy. J. Neuropathol. Exp. Neurol. 59:2000;393-397
15. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56(1):1997;70-78
16. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., Cowburn R.F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58(9):1999;1010-1019
17. Planel E., Yasutake K., Fujita S.C., Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J. Biol. Chem. 276(36):2001;34298-34306. (Epub: 2001, July 5)
18. Preece P., Virley D.J., Costandi M., Coombes R., Moss S.J., Mudge A.W., Jazin E., Cairns N.J. Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease. Brain Res. Mol. Brain Res. 116(1/2):2003;155-158
19. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9(8):1990;2431-2438
20. Woodgett J.R. Regulation and functions of the glycogen synthase kinase-3 subfamily. Semin. Cancer Biol. 5(4):1994;269-275